Refine your search

Content type
Firm name

613 results found


Quarles & Brady LLP | USA | 18 Feb 2020

2019 Wisconsin Insurance Case Law Year in Review

Over the last few years, Wisconsin appellate courts have issued a number of decisions relating to the duty to defend, beginning with Water Well


Kilpatrick Townsend & Stockton LLP | USA | 31 Jan 2020

January 31, 2020 Ninth Circuit deepens circuit split in pharmaceutical industry-specific RICO proximate cause ruling

Takeaway: To have standing to assert a civil RICO claim, federal RICO’s proximate cause requirement demands that there be a “direct relation” between


Morgan Lewis | USA | 15 Jan 2020

Federal Circuit: Inherency in an Obviousness Analysis

The US Court of Appeals for the Federal Circuit held that data obtained after an asserted patent’s priority date may be used to demonstrate what is


Cadwalader Wickersham & Taft LLP | USA | 2 Jan 2020

Individual Settles SEC Charges for Insider Trading

An individual settled SEC charges for trading on material, nonpublic information concerning an oncoming tender offering. According to the SEC's


Davies Collison Cave | Singapore | 19 Dec 2019

How Distinctive is your Abbreviation? Abbott Laboratories opposes Nestlé’s application for “HM-O” in Singapore.

Société des Produits Nestlé S.A. (Applicant) applied to register “HM-O” in Classes 5 and 29 for goods including ‘powdered milk for babies’ and ‘milk’


Reed Smith LLP | USA | 18 Nov 2019

Limits to Duty 2.0 On Product Manufacturers Supervising Doctors

Manufacturers supervising medical doctors? In two words, they don’t. Yet plaintiffs, particularly in cases where preemption forecloses more normal


Bradley Arant Boult Cummings LLP | USA | 12 Nov 2019

Yet Another Pharmaceutical Patent Falls Under the Scrutiny of 35 U.S.C. 112

Last week, the Federal Circuit confirmed that Idenix Pharmaceuticals will not be the proud recipient of what was previously regarded as the largest


Global Competition Review | USA, European Union | 31 Oct 2019

Negotiating the Remedy: A Practitioner’s Perspective

Remedies are a key part of the merger control planning process. While it is up to the parties to propose and implement remedies, their exact form and


Global Competition Review | India | 31 Oct 2019

Global competition around the world : India

A broad distinction may be drawn between modifications in the Phase I review, where the parties alone may offer modifications to the CCI


Reed Smith LLP | USA | 10 Oct 2019

Following More Than Just Money

In our How Not To Create an “Exception” to the Learned Intermediary Rule post two years ago, we criticized a couple of Texas trial court cases for

Previous page 1 2 3 ...